- Report
- April 2023
- 112 Pages
Global
From €4562EUR$4,750USD£3,928GBP
- Report
- April 2021
- 121 Pages
Middle East, Africa
From €2017EUR$2,100USD£1,736GBP
€2881EUR$3,000USD£2,481GBP
- Report
- April 2021
- 116 Pages
From €2017EUR$2,100USD£1,736GBP
€2881EUR$3,000USD£2,481GBP
- Report
- May 2022
- 76 Pages
North America
From €1441EUR$1,500USD£1,240GBP
- Report
- April 2023
- 110 Pages
Global
From €4562EUR$4,750USD£3,928GBP
- Report
- July 2021
- 99 Pages
Global
From €3200EUR$3,569USD£2,851GBP
- Book
- July 2021
- 392 Pages
- Report
- February 2022
- 113 Pages
Global
From €4322EUR$4,500USD£3,721GBP
- Report
- September 2022
- 141 Pages
Global
From €3429EUR$3,570USD£2,952GBP
- Book
- October 2018
- 528 Pages
The Neurodegenerative Disease market is a subset of the Neurosciences field that focuses on the diagnosis, treatment, and prevention of diseases that cause the progressive loss of structure or function of neurons, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). These diseases are characterized by the gradual degeneration of the nervous system, leading to a decline in cognitive and motor functions. Treatment options for these diseases are limited, and there is currently no cure.
The Neurodegenerative Disease market is composed of a variety of companies, including pharmaceutical companies, biotechnology companies, medical device companies, and research organizations. Examples of companies in this market include AbbVie, Biogen, Novartis, Merck, and Pfizer. Show Less Read more
